CONFERENCE UPDATE: AAN 2021
Efficacy and safety of intranasal zavegepant for the acute treatment of migraine
Rimegepant showed benefits for acute treatment and prevention of migraine in adult women - a post-hoc analysis
Migraine exhibits a 2-3 fold higher prevalence in women compared to men.1 Among females, migraines are typically of longer duration, more debilitating, and more likely to recur post-initial treatment.1 Studies have found that triptans were ineffective in up to 40% of migraine attacks.1 Rimegepant,